Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Safety and Tolerability of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT03854721 is registered in ClinicalTrials.gov with Vaxiion Therapeutics as lead sponsor.

NCT NCT03854721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03854721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Safety and Tolerability of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer (NMIBC)
Lead sponsor
Vaxiion Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
May 10, 2019
Completion date
March 1, 2023
Enrollment
6 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma of the urinary bladder